Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies

NEXT STORY
Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, and Competitive Landscape – Analysis and Forecast, 2019-2029
PREV STORY
MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers

In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 ...

author_avatar
NASDAQ Market News

Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

author_avatar
NASDAQ Market News

Protech Announces Execution of LOI to Acquire a Profitable Leading Supplier of Respiratory Therapy Products and Services in the Southeastern U.S.

author_avatar
NASDAQ Market News